Extended Data Fig. 5: LSD1 enhances AR-V7 chromatin binding and activity.
From: Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
a, ChIP-qPCR for FOXA1 binding at AR-regulated enhancers in LNCaP stable cells expressing doxycycline-inducible ARV7 (LNCaP-tetARV7) treated with/without GSK2879552 (50 μM, 4 h). b, Immunoblotting for V5 (AR-V7) in LNCaP-tetARV7 cells treated with vehicle, doxycycline only, doxycycline plus GSK2879552 (10 μM), doxycycline plus S2101 (10 μM), or doxycycline plus ORY-1001 (2.5 μM) for 48 h. c, RT-qPCR for the expression of AR-V7-regulated genes in CWR22-RV1 cells treated with GSK2879552 (0-2.5 μM for 48 h). d, Immunoblotting for AR-V7 in CWR22-RV1 cells treated with GSK2879552 (0-10 μM, 48 h). e, RT-qPCR for AR-FL/V7-regulated genes in the LSD1-KO line versus the control line with/without 10 nM DHT treatment. Note: Experiments described in this figure were all done under hormone-depleted conditions.
